Human-derived Treg and MSC combination therapy may augment immunosuppressive potency in vitro, but did not improve blood brain barrier integrity in an experimental rat traumatic brain injury model
Autor: | Naama E. Toledano Furman, Cecilia Martin, Karthik S. Prabhakara, Henry W. Caplan, Soheil Zorofchian, Charles S. Cox, Scott D. Olson, Hasen Xue |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Central Nervous System
Male Critical Care and Emergency Medicine Traumatic Brain Injury Physiology Cancer Treatment Nervous System T-Lymphocytes Regulatory Rats Sprague-Dawley Immune Physiology Cellular types Brain Injuries Traumatic Medicine Immune Response Trauma Medicine Multidisciplinary Immune cells Regulatory T cells Body Fluids medicine.anatomical_structure Blood Oncology Blood-Brain Barrier White blood cells medicine.symptom Anatomy Traumatic Injury Research Article Cell biology Blood cells Combination therapy Traumatic brain injury Science Immunology T cells Inflammation Cytokine Therapy Blood–brain barrier Mesenchymal Stem Cell Transplantation Immune system In vivo Immune Tolerance Animals Humans Neuroinflammation Medicine and health sciences Biology and life sciences business.industry Mesenchymal stem cell Mesenchymal Stem Cells medicine.disease Rats Disease Models Animal Animal cells Cancer research business Neurotrauma Spleen |
Zdroj: | PLoS ONE PLoS ONE, Vol 16, Iss 5, p e0251601 (2021) |
ISSN: | 1932-6203 |
Popis: | Traumatic brain injury (TBI) causes both physical disruption of the blood brain barrier (BBB) and altered immune responses that can lead to significant secondary brain injury and chronic inflammation within the central nervous system (CNS). Cell therapies, including mesenchymal stromal cells (MSC), have been shown to restore BBB integrity and augment endogenous splenic regulatory T cells (Treg), a subset of CD4+ T cells that function to regulate immune responses and prevent autoimmunity. We have recently shown that infusion of human cord blood-derived Treg decreased neuroinflammation after TBI in vivo and in vitro. However, while both cells have demonstrated anti-inflammatory and regenerative potential, they likely utilize differing, although potentially overlapping, mechanisms. Furthermore, studies investigating these two cell types together, as a combination therapy, are lacking. In this study, we compared the ability of Treg+MSC combination therapy, as well as MSC and Treg monotherapies, to improve BBB permeability in vivo and suppress inflammation in vitro. While Treg+MSC combination did not significantly augment potency in vivo, our in vitro data demonstrates that combination therapy may augment therapeutic potency and immunosuppressive potential compared to Treg or MSC monotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |